DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and seventy-six approved drugs.

There are thirty-seven US patents protecting TEVA PHARM drugs. There are thirty-eight tentative approvals on TEVA PHARM drugs.

There are four hundred and ninety-eight patent family members on TEVA PHARM drugs in forty-two countries and five hundred and seventy-three supplementary protection certificates in sixteen countries.

Summary for Teva Pharm

International Patents:	498
US Patents:	37
Tradenames:	232
Ingredients:	226
NDAs:	276
Patent Litigation for Teva Pharm:	See patent lawsuits for Teva Pharm
PTAB Cases with Teva Pharm as petitioner:	See PTAB cases with Teva Pharm as petitioner

Drugs and US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	MONTELUKAST SODIUM	montelukast sodium	TABLET, CHEWABLE;ORAL	078723-002	Aug 3, 2012	AB	RX	No	No
Teva Pharms Usa	AMLODIPINE BESYLATE AND VALSARTAN	amlodipine besylate; valsartan	TABLET;ORAL	091235-001	Mar 30, 2015		DISCN	No	No
Teva Pharms	VALACYCLOVIR HYDROCHLORIDE	valacyclovir hydrochloride	TABLET;ORAL	077655-001	May 24, 2010	AB	RX	No	No
Teva Pharms Usa	ROSIGLITAZONE MALEATE AND GLIMEPIRIDE	glimepiride; rosiglitazone maleate	TABLET;ORAL	078709-001	Apr 1, 2016		DISCN	No	No
Teva Pharms Usa	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	TABLET;ORAL	065096-001	Oct 29, 2002	AB	RX	No	No

Expired US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	6,054,430
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,054,430
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017	6,446,627
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-002	Jan 27, 2017	6,446,627
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	7,199,098

Paragraph IV (Patent) Challenges for TEVA PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Pharm Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	3501584
Uruguay	26796
European Patent Office	3057637
World Intellectual Property Organization (WIPO)	0200280
Japan	2018503687

Supplementary Protection Certificates for Teva Pharm Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0481754	SPC/GB06/032	United Kingdom		PRODUCT NAME: ENTECAVIR-(2-AMINO-1,9-DIHYDRO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE CYCLOPENTYL)-6H-PURIN-6-ONE AND HYDRATES THEREOF, PARTICULARLY THE MONOHYDRATE; REGISTERED: UK EU/1/06/343/001 20060626; UK EU/1/06/343/002 20060626; UK EU/1/06/343/003 20060626; UK EU/1/06/343/004 20060626; UK EU/1/06/343/005 20060626
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
1746976	2017C/027	Belgium		PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1280520	92678	Luxembourg		PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
1663240	300851	Netherlands		PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms